Meng Xi, Sun Hongfu, Cui Tiantian, Huang Wei
The Second Affiliated Hospital of Shandong First Medical University, Tai'an, Shandong, China.
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Future Oncol. 2024 Dec;20(40):3397-3402. doi: 10.1080/14796694.2024.2432290. Epub 2024 Nov 26.
Although concurrent Chemoradiotherapy (cCRT) is presently the standard intervention for patients with inoperable, locally advanced Esophageal Squamous Cell Carcinoma (ESCC), it has been associated with poor long-term survival outcomes. Notably, Immune Checkpoint Inhibitors (ICIs) improve the long-term survival of Esophageal Cancer (EC) patients, with manageable Adverse Effects (AEs). Herein, 90 patients with residual pathology after radical simultaneous Radiotherapy (RT) for inoperable/refused-to-operate ESCC were enrolled and randomized into two treatment groups (Chemotherapy+immunotherapy and chemotherapy alone) in a 2:1 ratio. This study will also discuss the value of immunotherapy in improving long-term survival outcomes in patients with pathological residuals after concurrent RT for locally advanced, inoperable ESCC.Clinical trial registration: http://www.chictr.org.cn/identifier is ChiCTR2200063345.
尽管同步放化疗（cCRT）目前是不可切除的局部晚期食管鳞状细胞癌（ESCC）患者的标准干预措施，但它与较差的长期生存结果相关。值得注意的是，免疫检查点抑制剂（ICIs）可改善食管癌（EC）患者的长期生存，且不良反应（AEs）可控。在此，90例因不可切除/拒绝手术的ESCC接受根治性同步放疗（RT）后有残留病理的患者被纳入研究，并按2:1的比例随机分为两个治疗组（化疗+免疫治疗和单纯化疗）。本研究还将探讨免疫治疗在改善局部晚期、不可切除的ESCC同步放疗后有病理残留患者的长期生存结果方面的价值。临床试验注册：http://www.chictr.org.cn/标识符为ChiCTR2200063345。
